



# 2009

european drug discovery  
product innovation award



## **Xenometrix AG**

*The “2009 European Drug Discovery Product Innovation Award,” is presented to Xenometrix AG, a privately held company headquartered in Allschwil, Switzerland, dedicated to providing high quality mutagenicity and cytotoxicity test systems since 1995. The award is in recognition of the company’s active role in the production of single and multiple endpoint cytotoxicity assays. These test kits are used in the early screening stages of drug discovery. One product line is the IN CYTOTOX PAN I kit that enables researchers to detect 4 main toxicity parameters on a single sample that is hard to match using certain kits from other life science organisations. Having a pipeline of highly innovative products, combined with top quality management and sales force, Xenometrix AG will support the drug development process, identifying non-druggable targets earlier in the cycle, saving pharmaceutical and biotechnology companies’ considerable time and money. These factors, thus, make Xenometrix AG the worthy recipient of this accolade.*

**Dr Laleh Safinia, Senior Analyst, Healthcare, Frost & Sullivan**

*Thanking you on behalf of the staff of Xenometrix, we appreciate and we feel very honoured by the Award. Your recognition is our motivation to continue further developments for efficient, reliable cytotoxicity assays and to contribute to the improvements of drug discovery, as well as of identification of chemical and environmental toxicants.*

**Dr. Nicole Weiland, CEO, Xenometrix AG**